Pharmaceutical companies will be forced to disclose their drug development costs, including for cancer therapies, under the drug price transparency mechanism, says Khairy Jamaluddin.
APHM and PhAMA indicate possible medicine price hikes due to “significant” increases in the cost of logistics, active pharmaceutical ingredients (APIs), and labour.
US-based PhRMA also says a policy is needed to bridge the gap for patients from the end of a clinical trial to listing in Malaysia’s Ministry of Health Medicines Formulary.
The median procurement price for originator drugs across the public and private sectors in Malaysia is about 8 times higher than international reference prices.